Does valerian help you sleep? The evidence is weak and mixed

Valerian, one of the most widely sold herbal sleep aids, has not been shown to reliably improve sleep: the most-cited meta-analysis, pooling 16 trials and 1,093 patients, found only a faint signal that it might help — and evidence of publication bias inflating even that [s1]. The American Academy of Sleep Medicine, weighing this class of evidence, suggests that clinicians not use valerian to treat insomnia in adults [s2].

That is a more honest answer than the packaging gives. Extracts of the root of Valeriana officinalis are marketed for inducing sleep and improving its quality, and the plant has a long traditional history, but tradition and a clinical effect are different things, and the trials that would settle it are mostly small and poorly built.

What the pooled trials actually found

The systematic review searched the literature for randomised, placebo-controlled trials of valerian for sleep quality and identified 16 eligible studies covering 1,093 patients [s1]. Its central caveat is not a footnote: most of the studies had significant methodologic problems, and the valerian doses, preparations and length of treatment varied considerably from trial to trial [s1]. When products and doses differ that much, pooling them measures an average of many things rather than one.

The one statistically significant result came from a yes-or-no measure. Six of the studies reported a dichotomous outcome — sleep improved or not — and together they showed a benefit, with a relative risk of improved sleep of 1.8 (95% confidence interval 1.2 to 2.9) [s1]. But the reviewers found evidence of publication bias in that same summary measure [s1], meaning trials showing nothing are likely missing from the record, which pushes an apparent benefit upward. Their bottom line was carefully hedged: the available evidence suggests valerian might improve sleep quality without producing side effects, and future studies should test standardised preparations with proper measures of sleep quality and safety [s1].

What the guideline concluded

When the American Academy of Sleep Medicine built its clinical practice guideline for treating chronic insomnia, it assessed individual agents one by one using the GRADE system, which rates the strength of the underlying evidence [s2]. For valerian, the recommendation is against: the guideline suggests that clinicians not use valerian as a treatment for sleep onset or sleep maintenance insomnia, versus no treatment, in adults [s2].

The strength assigned to that recommendation is "weak," and the distinction matters. Under GRADE, a weak recommendation reflects a lower degree of certainty rather than a demonstration that a treatment does not work [s2]. In other words, the guideline is not saying valerian has been proven useless; it is saying the evidence is too thin and too shaky to recommend it, and that on balance the harms, costs and uncertainties outweigh a benefit no one has reliably shown. Valerian sits in the same "suggest against" group as diphenhydramine, melatonin, tryptophan and trazodone [s2].

Why this keeps mattering

Insomnia affects roughly one-third of the adult population and drives higher rates of absenteeism, health-care use and social disability [s1], so the demand for an easy, natural fix is large and permanent. Valerian answers that demand commercially without answering it clinically. As a botanical supplement it is not held to the evidence standard a prescription hypnotic must meet, so a weak trial base is no barrier to sale.

None of this makes valerian dangerous on the current record — the meta-analysis noted no clear signal of side effects [s1] — and supplement products vary in what they contain. The gap is not proven harm but absent proof of benefit. For chronic insomnia, the same guidance framework and the wider field point first to cognitive behavioural therapy for insomnia, the intervention with the strongest and most durable evidence, before any pill or capsule.

This article describes what the trials and guidelines report and is not medical advice; decisions about treating insomnia belong with a clinician who knows the individual case.

Sources

• Valerian for Sleep: A Systematic Review and Meta-Analysis — The American Journal of Medicine, 2006-12-01
• Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults — Journal of Clinical Sleep Medicine (American Academy of Sleep Medicine), 2017-02-15